Project Grant R01CA281756

This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $691,118 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to establish a prospective cohort study of real-world multiple myeloma patients treated with chimeric antigen receptor (CAR) T-cell therapy.

The study aims to evaluate the relationships between psychosocial factors (e.g., depression, anxiety, social support) and immune-related factors (e.g., systemic inflammation, bone marrow immune microenvironment) with key clinical and patient-reported survivorship outcomes, including CAR T-cell toxicities, treatment response, progression-free survival, health-related quality of life, and symptom burden. The research will leverage patient-reported outcome assessments and biospecimen samples collected over a one-year period to characterize these factors and their associations with multiple myeloma survivorship after CAR T-cell therapy. Findings from this study are expected to inform the development of supportive care interventions and clinical decision-making tools to improve long-term outcomes for this growing patient population.